Extension Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema

PHASE2/PHASE3Enrolling by invitationINTERVENTIONAL
Enrollment

140

Participants

Timeline

Start Date

December 28, 2022

Primary Completion Date

June 30, 2027

Study Completion Date

June 30, 2027

Conditions
Hereditary AngioedemaHereditary Angioedema Type IHereditary Angioedema Type IIHereditary Angioedema Types I and IIHereditary Angioedema AttackHereditary Angioedema With C1 Esterase Inhibitor DeficiencyHereditary Angioedema - Type 1Hereditary Angioedema - Type 2C1 Esterase Inhibitor [C1-INH] DeficiencyC1 Esterase Inhibitor DeficiencyC1 Esterase Inhibitor, Deficiency ofC1 Inhibitor DeficiencyHereditary Angioedema Type IIIHereditary Angioedema (HAE)Hereditary Angioedema Type I and II
Interventions
DRUG

deucrictibant selected dose

deucrictibant soft capsule for oral use

Trial Locations (63)

918

Study site, San Juan

927

Study site, San Juan

1088

Study site, Budapest

1090

Study site, Vienna

1431

Study site, Sofia

1680

Study site, Sofia

2560

Study site, Campbelltown

4400

Study site, Salta

7700

Study site, Cape Town

8036

Study site, Graz

11471

Study site, Riyadh

12203

Study site, Berlin

17033

Study site, Hershey

20097

Study site, Milan

20138

Study site, Milan

20815

Study site, Chevy Chase

22185

Study site, Lund

23538

Study site, Lübeck

28007

Study site, Madrid

34093

Study site, Istanbul

35128

Study site, Padua

35209

Study site, Birmingham

38043

Study site, Grenoble

41944

Study site, Daegu

48202

Study site, Detroit

60590

Study site, Frankfurt am Main

60596

Study site, Frankfurt am Main

63141

Study site, St Louis

72205

Study site, Little Rock

75231

Study site, Dallas

75571

Study site, Paris

78278

Study site, Ashkelon

80131

Study site, Napoli

80907

Study site, Colorado Springs

85258

Study site, Scottsdale

90146

Study site, Palermo

90404

Study site, Santa Monica

92122

Study site, San Diego

94598

Study site, Walnut Creek

95124

Study site, Catania

02115

Study site, Boston

B1629AHJ

Study site, Buenos Aires

41950-640

Study site, Salvador

14048-900

Study site, Ribeirão Preto

09060-870

Study site, Santo André

05403-000

Study site, São Paulo

T6G 1Z1

Study site, Edmonton

Unknown

Study site, Montreal

Study site, Hong Kong

602 00

Study site, Brno

00133

Study site, Roma

730-8518

Study site, Hiroshima

216-8511

Study site, Kanagawa

569-8686

Study site, Osaka

113-8431

Study site, Tokyo

133-8431

Study site, Tokyo

1005 AZ

Study site, Amsterdam

31-503

Study site, Krakow

03080

Study site, Seoul

08035

Study site, Barcelona

08907

Study site, Barcelona

06230

Study site, Ankara

E1 2ES

Study site, London

All Listed Sponsors
lead

Pharvaris Netherlands B.V.

INDUSTRY